Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133458
Status:
WITHDRAWN
Last Update Posted:
2019-01-30
First Post:
2005-08-19
Brief Title:
RCT ALB for SA Cysticercosis
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Randomized Double Blind Comparison of Two Lenghts of Albendazole Therapy for Subarachnoid Cysticercosis
Status:
WITHDRAWN
Status Verified Date:
2005-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will enroll 120 individuals diagnosed with subarachnoid cysticercosis a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite This study will determine if two months of albendazole ABZ therapy is better than one-month The study will last 3 years
Detailed Description:
This is a randomized double blind comparison of two lengths of albendazole thereapy for subarachnoid cysticercosis It will enroll 120 individuals male and female age 18 to 65 and diagnosed with subarachnoid cysticercosis a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite This study will determine if two months of albendazole ABZ therapy is better than one-month The study will last 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None